Sebacia Postmarket Study of Real-World Use

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03818555
Recruitment Status : Recruiting
First Posted : January 28, 2019
Last Update Posted : January 28, 2019
Information provided by (Responsible Party):
Sebacia, Inc.

Brief Summary:
Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Other: Sebacia Microparticles Treatment Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Prospective, Multicenter, Postmarket Study of Sebacia Microparticles Treatment in Patients Using Topical Acne Products for Mild to Moderate Inflammatory Acne Vulgaris
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Sebacia Microparticles Treatment Other: Sebacia Microparticles Treatment
Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
Other Name: Sebacia treatment, Microparticles and Nd:Yag laser treatment

Primary Outcome Measures :
  1. Inflammatory Lesion Count [ Time Frame: Months 2, 3, 6, 9 and 12 ]
    Percent change in number of inflammatory lesions from baseline

Secondary Outcome Measures :
  1. Investigator's Global Assessment [ Time Frame: Months 2, 3, 6, 9 and 12 ]
    Percent of subjects clear (IGA 0) or almost clear (IGA 1)

  2. Physician's Overall Assessment of Improvement [ Time Frame: Months 2, 3, 6, 9 and 12 ]
    Categorical improvement from baseline (worse, no change, minimal, moderate, marked, complete)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild to moderate facial inflammatory acne vulgaris (IGA 2 or 3)
  • Between 10 and 50 papules/pustules
  • Fitzpatrick skin phototype I, II or III
  • Able to provide informed consent and comply with study schedule and other requirements

Exclusion Criteria:

  • Moderately severe or severe acne vulgaris (IGA 4 or 5)
  • Nodulocystic acne, significant scarring or excoriation
  • Requires oral retinoid, antibiotic or corticosteroid for acne
  • New or fluctuating hormone or hormone-regulating therapy
  • Photosensitivity or allergy to gold
  • Medical or mental health condition that would pose a risk to patient or impair treatment and evaluation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03818555

Contact: VP, Clinical & Regulatory Affairs 770-688-1280
Contact: Study Support

United States, Florida
Miami Dermatology & Laser Institute Recruiting
Miami, Florida, United States, 33173
Contact: Clinical Trials Office    305-279-6060      
United States, Massachusetts
Dermatology Institute of Boston Recruiting
Boston, Massachusetts, United States, 02116
Contact: Study Coordinator   
United States, Tennessee
International Clinical Research Recruiting
Murfreesboro, Tennessee, United States, 37130
Contact: Study Recruiter    615-410-3460      
United States, Texas
Austin Institute for Clinical Research - Central Recruiting
Austin, Texas, United States, 78705
Contact: Study Coordinator    512-454-3781      
Austin Institute for Clinical Research - Pflugerville Recruiting
Pflugerville, Texas, United States, 78660
Contact: Study Recruiter    512-279-2545      
United States, Washington
Premier Clinical Research Recruiting
Spokane, Washington, United States, 99202
Contact: Study Coordinator    509-343-3710      
Sponsors and Collaborators
Sebacia, Inc.
Study Director: VP, Clinical & Regulatory Affairs Sebacia, Inc.

Additional Information:
Responsible Party: Sebacia, Inc. Identifier: NCT03818555     History of Changes
Other Study ID Numbers: SEB-0550
First Posted: January 28, 2019    Key Record Dates
Last Update Posted: January 28, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases